Brief: Abbisko Cayman Says FGFR4 Mutant Inhibitor ABSK012 Granted Orphan Drug Designation By U.S. FDA
03/04/2023 02:09
April 3 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* FGFR4 MUTANT INHIBITOR ABSK012 GRANTED ORPHAN DRUG
DESIGNATION
BY U.S. FDA FOR TREATMENT OF SOFT TISSUE SARCOMA
Source text for Eikon: ID:nHKS95tDt4
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly